Browsing: Acute Lymphoblastic Leukemia
Anne L. Angiolillo, MD, MS, director of the Leukemia and Lymphoma Program at Children’s National Medical Center speaks about the…
Michael A. Pulsipher, MD from the Cancer and Blood Disease Institute, Children’s Hospital Los Angeles discusses Continued Role for Radiation…
Christina Peters, MD, Professor of Paediatrics of St. Anna Children’s Hospital, and the Children’s Cancer Research Institute speaks about Total…
Cutaneous T cell lymphoma (CTCL), a heterogeneous group of non-Hodgkin lymphomas is a rare but aggressive cancer that manifests primarily…
In this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Armon Sharei, Ph.D. Chief Executive Officer of SQZ…
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with…
David A. Reardon, MD Dana-Farber Cancer Institute discusses INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma…
Jeremy Warner, MD of Vanderbilt-Ingram Cancer Center @VUMC_Cancer discusses the clinical impact of COVID-19 on patients with cancer: data from…
Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Aaron C.…
Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’…
Earn CME: https://www.naccme.com/program/19-lm-04 In this webcast from the ‘Recent Advances in Acute Leukemia Management’ symposium during the 2019 Lymphoma &…
Tamer Othman, MD @tamerothman10 of Harbor-UCLA Medical Center @HarborUCLA answers common questions on the characteristics and trends in adult acute…
Tamer Othman, MD @tamerothman10 of Harbor-UCLA Medical Center @HarborUCLA discusses the characteristics and trends in adult acute lymphoblastic leukemia. The…
Neal Shore, MD of Carolina Urologic Research Center explains the randomized phase II study of sipuleucel-T with or without radium-223…
mms360CDX
mms360Heme
mms360Liquid
mms360portfolio
Test
American doctor and cancer research scientist, Dr. William G. Kaelin, Jr. (Harvard University and Dana Farber Cancer Institute), along with…
Final analysis expands on efficacy results from pivotal Phase III trial of Lumoxiti in hairy cell leukemia; durable, complete responses…
FMI-Roche-Portfolio
FMI-Roche-Liquid-PreRoll-Preview
FMI-Roche-Heme-PreRoll-Preview
Eytan Stein, MD of @sloan_kettering discusses the first patient dosed in phase 1/2 AUGMENT-101 trial of SNDX-5613 for the treatment…
Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of…
National Comprehensive Cancer Network hosts summit on defining, measuring, and applying quality in an evolving health policy landscape and the…
Phase One Study Shows Novel KRAS Inhibitor Well Tolerated by Patients with Adenocarcinoma and Non-Small Cell Lung Cancer Barcelona–Sunday, September…
(9 September, Tokyo) In a recent study published in the journal Haematologica, researchers at Juntendo University used stem cell technology to…
Phase 3 Data for KEYTRUDA® (pembrolizumab) as Neoadjuvant Therapy in Combination with Chemotherapy in Patients with Triple-Negative Breast Cancer (KEYNOTE-522) to…
54% of 13 Evaluable Non-Small Cell Lung Cancer Patients Experienced a Partial Response at the Target Dose of 960 mg…
TORONTO, ON and LONDON, UK / ACCESSWIRE / September 6, 2019 /Â Soricimed Biopharma Inc. (“Soricimed”), a clinical-stage pharmaceutical company discovering…
FINDINGS Breast cancer surgeons performing lumpectomies seek to spare healthy breast tissue while removing all cancerous cells, but determining appropriate…
Hamburg, Germany and Baltimore, Maryland, 2019.09.04 ̶ Using Sysmex Inostics’ novel SafeSEQ next- generation sequencing cell-free DNA technology, investigators from…
Yes. Screening techniques for ovarian cancer are nonexistent. Studies have looked at combinations of blood markers and ultrasounds, but they…
(Reuters Health) – Cancer specialists only rarely advise patients on lifestyle changes that could improve overall health and possibly also…
– Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one…
(New York, NY – September 3, 2019) – September is Thyroid Cancer Awareness Month,and doctors in the Mount Sinai Health System…
John Fruehauf, MD of UC Irvine Health discusses IMNC (International Neoadjuvant Melanoma Consoritum) Abstract 9503.
Afsaneh Barzi, MD of Keck School of Medicine discusses the immediate implications in the POLO trial is mandatory germline testing…
HATFIELD, Pa. and CLEVELAND, Aug. 27, 2019 /PRNewswire/ — Genisphere LLC and University Hospitals Cleveland Medical Center announced a partnership…